MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -77.02M | -73.47M | -61.92M | -55.18M | -47.20M |
| Total Depreciation and Amortization | 271.00K | 273.00K | 244.00K | 227.00K | 192.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.27M | 1.78M | 2.40M | 2.79M | 2.77M |
| Change in Net Operating Assets | 3.66M | 4.76M | 4.60M | 2.37M | 1.39M |
| Cash from Operations | -70.81M | -66.65M | -54.68M | -49.79M | -42.85M |
| Capital Expenditure | -886.00K | -631.00K | -874.00K | -837.00K | -802.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -138.04M | -172.17M | -159.72M | -121.37M | -39.22M |
| Cash from Investing | -138.92M | -172.80M | -160.60M | -122.21M | -40.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 176.04M | 174.76M | 174.95M | 174.77M | 275.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 63.50M | 63.50M | 63.50M | 63.50M | 68.51M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.52M | -4.34M | -4.34M | -4.01M | -1.85M |
| Cash from Financing | 237.01M | 233.93M | 234.10M | 234.26M | 66.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 27.28M | -5.52M | 18.83M | 62.26M | -15.94M |